Genection's MyAML NGS Assay

Genection has launched MyAML, a CLIA-validated next-generation sequencing assay that identifies clinically actionable, pathogenic, and potentially pathogenic mutations in 194 genes associated with acute myeloid leukemia. The panel identifies single-nucleotide variants, insertion-deletion variants, and the entire range of structural variants, including partial tandem duplications and translocations, Genection said.